Advertisement

Topics

Erdheim-chester disease.

06:00 EDT 3rd September 2010 | BioPortfolio

Summary of "Erdheim-chester disease."

No Summary Available

Affiliation

St. Michael's Hospital - Medicine, 30 Bond St., Toronto, Ontario M5B 1W8, Canada. leeyuna@smh.toronto.on.ca.

Journal Details

This article was published in the following journal.

Name: The Journal of rheumatology
ISSN: 0315-162X
Pages: 1962-3

Links

DeepDyve research library

PubMed Articles [16237 Associated PubMed Articles listed on BioPortfolio]

Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease.

Erdheim-Chester disease is a rare xanthogranulomatous systemic disease, which involves the orbit in some cases. Through this case report, the authors review the treatment modalities used in orbital Er...

Usefulness of nuclear medicine in Erdheim-Chester disease: A Lille experience.

Erdheim-Chester disease is a rare form of non-langerhans histiocytosis and its etiology is still not well established. The aims of the study were to assess the value of the bone scintigraphy and the (...

Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease.

While cladribine is best known for the treatment of hairy cell leukemia and other lymphoid cancers, it also has activity against myeloid neoplasms, such as Erdheim-Chester disease (ECD).

Erdheim-Chester Disease presenting with histiocytic colitis and cytokine storm.

Non-Langerhans histiocytosis is a group of inflammatory lymphoproliferative disorders originating from non-clonal expansion of hematopoietic stem cells into cytokine-secreting dendritic cells or macro...

18F-FDG PET/CT in Erdheim-Chester disease.

Clinical Trials [2209 Associated Clinical Trials listed on BioPortfolio]

Clinical and Basic Investigations Into Erdheim Chester Disease

Background: - Erdheim Chester Disease (ECD) is a very rare disease in which abnormal white blood cells start growing and affect the bones, kidneys, skin, and brain. ECD can cause severe l...

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

Erdheim-Chester Diseases (ECD) is a very rare non-Langerhans cell histiocytosis of unknown origin and pathogenesis. It has been reported mainly in adult males over the age of 40 years, alt...

Telemonitoring Enhanced Support for Depression Self Management

The objective of this research is to test the efficacy of "CarePartners for Depression" (CP-D) intervention, which was designed to increase between visit monitoring of depression status an...

Type 1 Multiple Endocrine Neoplasia Cohort Study

Type 1 - Multiple Endocrine Neoplasia syndrome (MEN1,) is an autosomal dominant disorder secondary to MEN1 mutations that predisposes carriers to endocrine tumors. The MEN1 gene located on...

Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients

Obstructive sleep apnea (OSA) and obesity is associated with increased perioperative morbidity and mortality. This group of patients is at risk of perioperative desaturations which can be ...

Medical and Biotech [MESH] Definitions

A rare form of non-Langerhans-cell histiocytosis (HISTIOCYTOSIS, NON-LANGERHANS-CELL) with onset in middle age. The systemic disease is characterized by infiltration of lipid-laden macrophages, multinucleated giant cells, an inflammatory infiltrate of lymphocytes and histiocytes in the bone marrow, and a generalized sclerosis of the long bones.

Animate or inanimate sources which normally harbor disease-causing organisms and thus serve as potential sources of disease outbreaks. Reservoirs are distinguished from vectors (DISEASE VECTORS) and carriers, which are agents of disease transmission rather than continuing sources of potential disease outbreaks.

Analyses for a specific enzyme activity, or of the level of a specific enzyme that is used to assess health and disease risk, for early detection of disease or disease prediction, diagnosis, and change in disease status.

The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.

Immune-mediated inflammation of the PITUITARY GLAND often associated with other autoimmune diseases (e.g., HASHIMOTO DISEASE; GRAVES DISEASE; and ADDISON DISEASE).

Quick Search
Advertisement
 


DeepDyve research library

Searches Linking to this Article